OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

HHS issues AI strategy for internal agency operations

HHS has issued its AI strategy—“the first step” in making a “whole-of-department transformation” towards the use of artificial intelligence in public health, health care delivery, biomedical research, human services, and agency operations.

AI will determine Medicare prior authorizations in six states under new pilot program

Medicare will soon launch a pilot program that will test the use of AI to automate the prior authorization process—a tool that will recommend whether to approve or deny coverage for a patient in the program.

December 12, 2025

Vol.51 No.45

By Sara Willa Ernst

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows

Imaging assessments are a requirement for most oncology trial endpoints. Yet, many cancer centers are still trying to support research trials with clinical care tools and ad hoc processes that are not fit-for-purpose and don’t meet the needs of sponsors or trial staff.

Jihad Obeid named assistant vice president for research at MUSC

Jihad Obeid was appointed as assistant vice president for research for AI Strategy & Research Intelligence at the Medical University of South Carolina.

December 05, 2025

Vol.51 No.44

Drugs & Targets

Université Paris-Saclay, Owkin partner to use AI co-pilot for biology research

Xavier Apolinarski (left), vice president of innovation at Université Paris-Saclay, and Eric Durand (right), chief research and technology officer at Owkin at the signing of the deal between Université Paris-Saclay and Owkin.Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free—Owkin’s AI co-pilot for biology—for use by Université Paris-Saclay.

December 05, 2025

Vol.51 No.44

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

YOU MAY BE INTERESTED IN

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

HHS issues AI strategy for internal agency operations

AI will determine Medicare prior authorizations in six states under new pilot program

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows

Jihad Obeid named assistant vice president for research at MUSC

Université Paris-Saclay, Owkin partner to use AI co-pilot for biology research

Renew today!

Subscriber content

Never miss an issue!

Login

OmniaBio opens commercial manufacturing facility in Canada, bringing cell and gene therapies to patients

YOU MAY BE INTERESTED IN

ESMO publishes guidances on AI tools for clinicians, patients, and researchersSays one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

HHS issues AI strategy for internal agency operations

AI will determine Medicare prior authorizations in six states under new pilot program

Fixing site reads without burning out the readersYunu modernizes clinical trial imaging assessment workflows

Jihad Obeid named assistant vice president for research at MUSC

Université Paris-Saclay, Owkin partner to use AI co-pilot for biology research

Never miss an issue!

Login

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

Fixing site reads without burning out the readers
Yunu modernizes clinical trial imaging assessment workflows